TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16479517

Group type: EXPERIMENTAL
Intervention: MCV-4
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: MPSV-4
Number of subjects: 160
Study: 12926339

Group type: EXPERIMENTAL
Intervention: Active surgical policy based on prognosis of bleeding recurrence probability
Number of subjects: 818

Group type: COMPARATOR
Intervention: Systemic hemostatic therapy, antisecretory drugs, methods of endoscopic hemostasis
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Dynamical determination of pO2 in periulcerous zone
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Recurrence of gastroduodenal ulcer bleeding
Number of subjects: 818
Study: 10856108

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 414

Group type: COMPARATOR
Intervention: Conventional amphotericin B
Number of subjects: 414
Study: 9378690

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75-225 mg) once daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 8269047

Group type: EXPERIMENTAL
Intervention: Fixed appointment method
Number of subjects: 800

Group type: COMPARATOR
Intervention: Open letters of invitation
Number of subjects: 800
Study: 3081868

Group type: EXPERIMENTAL
Intervention: Early enteral feeding (initiated on day 1 of life)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Late enteral feeding (initiated on day 7 of life)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Minimally sick, very low birth weight neonates (control group)
Number of subjects: 34
Study: 27932625

Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (GECS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inverse graduated elastic compression stockings (PECS)
Number of subjects: 64
Study: 29949328

Group type: EXPERIMENTAL
Intervention: Tongkuaixiao ointment (TKXO)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 24752284

Group type: EXPERIMENTAL
Intervention: Immediate Training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed Training
Number of subjects: 50
Study: 21992858

Group type: EXPERIMENTAL
Intervention: Oral vitamin D (1000 IU for <1 year and 2000 IU for >1 year) once a day for 5 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (lactose) once a day for 5 days
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral vitamin D (1000-2000 IU per day for 5 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 200
Study: 20345740

Group type: EXPERIMENTAL
Intervention: 200 hours of accelerated artificial daylight aging
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 hours of accelerated artificial daylight aging
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 400 hours of accelerated artificial daylight aging
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 600 hours of accelerated artificial daylight aging
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 hours, 400 hours, and 600 hours of aging
Number of subjects: 40
Study: 18285358

Group type: EXPERIMENTAL
Intervention: PCI group (patients with a history of PCI)
Number of subjects: 2489

Group type: COMPARATOR
Intervention: Non-PCI group (patients without a history of PCI)
Number of subjects: 2489
Study: 15811151

Group type: EXPERIMENTAL
Intervention: Fragmented instructional video (8 short clips)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Complete sequential video
Number of subjects: 28
Study: 12723743

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine (10, 5, and 5 mg/kg) at 24-hour intervals
Number of subjects: 144

Group type: COMPARATOR
Intervention: Indomethacin (0.2 mg/kg at 12-hour intervals)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ibuprofen (prophylaxis)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 144
Study: 10229431

Group type: EXPERIMENTAL
Intervention: Active nonsteroidal antiinflammatory drugs (n=352)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Placebo (n=121)
Number of subjects: 423
Study: 8522712

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (525 mg/24 h)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (1,050 mg/24 h)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (2,100 mg/24 h)
Number of subjects: 273
Study: 1662325

Group type: EXPERIMENTAL
Intervention: Cuprophane membrane
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: AN 69 membrane
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 18
Study: 6811710

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ad libitum food intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bowel at rest and TPN
Number of subjects: 0
Study: 31444872

Group type: EXPERIMENTAL
Intervention: Augmented implementation facilitation
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Text messaging support
Number of subjects: 197

Group type: COMPARATOR
Intervention: Usual implementation
Number of subjects: 197
Study: 27828927

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg ketamine administered intravenously during ECT under propofol anesthesia
Number of subjects: 132

Group type: COMPARATOR
Intervention: Isovolumetric placebo (normal saline) administered during ECT under propofol anesthesia
Number of subjects: 132
Study: 24923232

Group type: EXPERIMENTAL
Intervention: High-protein breakfast (egg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control breakfast (steamed bread)
Number of subjects: 156
Study: 25171148

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 212

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 212
Study: 22974554

Group type: EXPERIMENTAL
Intervention: 10 Hz HF‐rTMS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study: 19201391

Group type: COMPARATOR
Intervention: Silicone IOL (CeeOn 911A; AMO)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (AcrySof MA60BM; Alcon)
Number of subjects: 44
Study: 18001250

Group type: EXPERIMENTAL
Intervention: Bromfenac ophthalmic solution 0.09%
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 15056183

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 11799287

Group type: EXPERIMENTAL
Intervention: ChemFlex (Dentsply DeTrey)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fuji IX GP (GC)
Number of subjects: 89
Study: 9728672

Group type: EXPERIMENTAL
Intervention: SSRIs (fluvoxamine, fluoxetine, paroxetine, sertraline) at recommended daily dosages for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7645712

Group type: EXPERIMENTAL
Intervention: Oxygen therapy by facemask
Number of subjects: 12

Group type: COMPARATOR
Intervention: Blinded air by facemask
Number of subjects: 12
Study: 2520418

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (5 mg/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous lidocaine and placebo
Number of subjects: 10
Study: 1092276

Group type: EXPERIMENTAL
Intervention: Monthly sulphadoxine-pyrimethamine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Weekly chloroquine
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study: 30120600

Group type: EXPERIMENTAL
Intervention: Sumatriptan (2 x 50 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sumatriptan and Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 30
Study: 27352250

Group type: EXPERIMENTAL
Intervention: Social app
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Affect app
Number of subjects: 95
Study: 24578607

Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (0.5% lidocaine, 4 mL) mixed with 1 mL or 6 mg of nonparticulate betamethasone
Number of subjects: 120
Study: 21885867

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic treadmill exercise (TAEX)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional care physiotherapy (Control)
Number of subjects: 38
Study: 20660280

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (HD-VA) supplement (209.8 micromol; 60 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Stable isotope (SI)-labeled vitamin A (17.5 micromol; 5 mg)
Number of subjects: 8
Study: 18355327

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus 1 OAD
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus >1 OAD
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Insulin glargine (both groups)
Number of subjects: 865
Study: 16331544

Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Dental computed tomography (Dental CT)
Number of subjects: 417
Study: 11331428

Group type: EXPERIMENTAL
Intervention: Sibutramine (30 mg)
Number of subjects: 15
Study: 9438978

Group type: EXPERIMENTAL
Intervention: 3 capsules of green tea extract (225 mg EGCg, 7.5 mg EGC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 5 capsules of green tea extract (375 mg EGCg, 12.5 mg EGC)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 7 capsules of green tea extract (525 mg EGCg, 17.5 mg EGC)
Number of subjects: 3
Study: 8175973

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (P)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham treatment (S)
Number of subjects: 18
Study: 3068971

Group type: EXPERIMENTAL
Intervention: 3-month exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 2773967

Group type: EXPERIMENTAL
Intervention: Orgotein (8 mg to 32 mg) administered as an intra-articular injection once a week for three weeks
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo administered as an intra-articular injection once a week for three weeks
Number of subjects: 139
Study: 31408137

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP goal < 120 mm Hg, n=355)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Standard treatment (SBP goal < 140 mm Hg, n=315)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP goal < 120 mm Hg)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Standard treatment (SBP goal < 140 mm Hg)
Number of subjects: 670
Study: 28549480

Group type: EXPERIMENTAL
Intervention: Academic detailing (AD) intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (standard practice)
Number of subjects: 40
Study: 26355618

Group type: EXPERIMENTAL
Intervention: Sunscreens plus DNA repair enzymes (enzyme group)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sunscreens alone (sunscreen group)
Number of subjects: 28
Study: 24367678

Group type: EXPERIMENTAL
Intervention: Nevirapine-based antiretroviral therapy
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy
Number of subjects: 573
Study: 21310350

Group type: EXPERIMENTAL
Intervention: Apical resection at 90° angle with MTA obturation (Group 1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Apical resection at 90° angle with ultrasonic preparation and MTA obturation (Group 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Apical resection at ∼45° angle with MTA obturation (Group 3)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Apical resection at ∼45° angle with ultrasonic preparation and MTA obturation (Group 4)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 46

Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 46
Study: 20030843

Group type: EXPERIMENTAL
Intervention: WEB-based behavioral intervention (12-week duration, starting 2 weeks post-implantation)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: WEB-based behavioral intervention
Number of subjects: 350
Study: 17113831

Group type: EXPERIMENTAL
Intervention: Nonpharmacological intervention (low in total and saturated fat, trans fats, higher in fiber, promotes loss of 7-10% of body weight, includes at least 150 min of physical activity per week)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Health education (control group)
Number of subjects: 508
Study: 15163773

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2950

Group type: COMPARATOR
Intervention: PSA level 0.5 ng/mL or less
Number of subjects: 2950

Group type: COMPARATOR
Intervention: PSA level 0.6 to 1.0 ng/mL
Number of subjects: 2950

Group type: COMPARATOR
Intervention: PSA level 1.1 to 2.0 ng/mL
Number of subjects: 2950

Group type: COMPARATOR
Intervention: PSA level 2.1 to 3.0 ng/mL
Number of subjects: 2950

Group type: COMPARATOR
Intervention: PSA level 3.1 to 4.0 ng/mL
Number of subjects: 2950
Study: 11210401

Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride (2.4 g doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (without sevelamer)
Number of subjects: 0
Study: 9596048

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (n = 24)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy with imipramine (n = 26)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Supportive psychotherapy (n = 24)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (n = 27)
Number of subjects: 101
Study: 8311598

Group type: EXPERIMENTAL
Intervention: Pulsatile flow during cardiopulmonary bypass
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nonpulsatile flow during cardiopulmonary bypass
Number of subjects: 10
Study: 3135734

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NTG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous nitroprusside (NTP)
Number of subjects: 40
Study: 31562059

Group type: EXPERIMENTAL
Intervention: bCPAP
Number of subjects: 644

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 644
Study: 29308591

Group type: EXPERIMENTAL
Intervention: Intranasal ELI‐200 (30‐mg oxycodone hydrochloride/3‐mg naltrexone HCl)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone immediate release (30‐mg oxycodone HCl)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral ELI‐200 (30mg/3mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fixed placebo
Number of subjects: 44
Study: 25192833

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 93

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 93
Study: 22842905

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 21507067

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.25 ATA with 32% oxygen for 1 h/day, three times per week for males; two times per week for females.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 1.25 ATA with 32% oxygen for 1 h/day, two times per week for females.
Number of subjects: 0
Study: 19198708

Group type: EXPERIMENTAL
Intervention: Oral dextromethorphan (45 mg)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 17167382

Group type: EXPERIMENTAL
Intervention: Recent advances in understanding diastolic heart failure (DHF)
Number of subjects: 0
Study: 15005303

Group type: EXPERIMENTAL
Intervention: Determined compliance in SAH group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Determined compliance in controlled group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) using maximum of first derivative of pressure waveform
Number of subjects: 0
Study: 11372025

Group type: EXPERIMENTAL
Intervention: Nvp and 3TC mutations detected frequently at virologic failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintained on study regimen after virologic failure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline drug resistance mutations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zdv, ddI, and ddC mutations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rtv and Nfv mutations
Number of subjects: 0
Study: 9656393

Group type: EXPERIMENTAL
Intervention: Artemether (150 and 100 mg) with mefloquine (750 and 500 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Artesunate (150 and 100 mg) with mefloquine (750 and 500 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Artemether with mefloquine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Artesunate with mefloquine
Number of subjects: 99
Study: 8386603

Group type: EXPERIMENTAL
Intervention: d-sotalol
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 3

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3
Study: 3112428

Group type: EXPERIMENTAL
Intervention: 85-cm open-ended, unweighted nasogastric feeding tube (Prima, Portex UK)
Number of subjects: 403

Group type: COMPARATOR
Intervention: 91-cm 3.0-g weighted tube (Entriflex, Biosearch, Raritan, NJ)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: New polyurethane nasogastric feeding tubes (one weighted and one unweighted)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Widely used PVC unweighted open-ended tube
Number of subjects: 403
Study: 30003367

Group type: EXPERIMENTAL
Intervention: Sad mood
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Happy mood
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Neutral mood
Number of subjects: 3
Study: 27687347

Group type: EXPERIMENTAL
Intervention: Sugammadex (4 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Neostigmine (0.05 mg/kg) and Atropine (0.01 mg/kg)
Number of subjects: 50
Study: 24742955

Group type: COMPARATOR
Intervention: Exercise alone (E; n = 95)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Dietary‐induced weight loss (D; n = 88)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Combination of dietary‐induced weight loss and exercise (D + E; n = 101)
Number of subjects: 284
Study: 22520138

Group type: EXPERIMENTAL
Intervention: PRV (pentavalent rotavirus vaccine)
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: PRV
Number of subjects: 1308
Study: 20019677

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (<30 g/day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Low-fat diet (≤30% of calories from fat with a deficit of 500 kcal/day)
Number of subjects: 144
Study: 18807900

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube Suction (LTS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Proseal Laryngeal Mask Airway (PLMA)
Number of subjects: 40
Study: 15810646

Group type: COMPARATOR
Intervention: Rifaximin, 200 mg bid (Group R1: 39 pts)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Rifaximin, 400 mg bid (Group R2: 43 pts)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Mesalazine, 400 mg bid (Group M1: 40 pts)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Mesalazine, 800 mg bid (Group M2: 48 pts)
Number of subjects: 170
Study: 12375668

Group type: EXPERIMENTAL
Intervention: Prophylactic calcium (Ca) chloride or Ca gluconate at a dose linked to citrate infusion rate (1.0‐2.2 mg/kg/min)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Prophylactic calcium (Ca) chloride
Number of subjects: 315

Group type: COMPARATOR
Intervention: Citrate anticoagulation without prophylactic calcium
Number of subjects: 315

Group type: COMPARATOR
Intervention: Citrate administration
Number of subjects: 315
Study: 10100361

Group type: EXPERIMENTAL
Intervention: Contact laser vaporization (CLV)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 50
Study: 7842770

Group type: EXPERIMENTAL
Intervention: Furosemide (10 mg/m2 of body)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amiloride (0.3 mg/m2 of body)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 12
Study: 1974124

Group type: EXPERIMENTAL
Intervention: Formoterol (injected intradermally, 2 min prior to challenge)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terbutaline (injected intradermally, 2 min prior to challenge)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of Formoterol and Terbutaline
Number of subjects: 0
Study: 651283

Group type: EXPERIMENTAL
Intervention: 1 mg lanatosid C in saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corresponding volume of saline (placebo)
Number of subjects: 0
Study: 31923712

Group type: EXPERIMENTAL
Intervention: Whole Pelvic Radiation Therapy (WPRT, 68 Gy/25# to prostate and 50 Gy/25# to pelvis)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Prostate Only Radiation Therapy (PORT, 68 Gy/25# to prostate)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Whole Pelvic Radiation Therapy (WPRT)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Prostate Only Radiation Therapy (PORT)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Whole Pelvic Radiation Therapy (WPRT) and Prostate Only Radiation Therapy (PORT)
Number of subjects: 224
Study: 31429019

Group type: EXPERIMENTAL
Intervention: Shave group
Number of subjects: 181

Group type: COMPARATOR
Intervention: No-shave group
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Shave group (C-E cup breasts)
Number of subjects: 181

Group type: COMPARATOR
Intervention: No-shave group (C-E cup breasts)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Shave group (A-B cup breasts)
Number of subjects: 181

Group type: COMPARATOR
Intervention: No-shave group (A-B cup breasts)
Number of subjects: 181
Study: 28810731

Group type: EXPERIMENTAL
Intervention: EhimNTf2/water mixtures at 2:1 and 1:1 concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EmimNTf2/water mixtures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EhimNTf2/water mixtures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FT-IR spectra analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OHD-OKE experiments
Number of subjects: 0